Bionano Announces Presentation of Optical Genome Mapping Utility Across Cancer Research Applications at the Cancer Genomics Consortium (CGC) 2024 Annual Meeting
01. August 2024 08:00 ET
|
Bionano Genomics
SAN DIEGO, Aug. 01, 2024 (GLOBE NEWSWIRE) -- A sponsored exhibitor session will feature Dr. Phillip Michaels from Harvard Medical School and Brigham and Women’s Hospital presenting data from a...
Scientific Presentations Highlight OGM’s Utility for Cancer Research at Joint Annual Meeting for Three Molecular and Cytogenetic Associations
02. Juli 2024 08:00 ET
|
Bionano Laboratories
At a sponsored workshop, Su Yang from The University of Texas MD Anderson Cancer Center will present case studies that demonstrate the ability of the optical genome mapping (OGM) workflow to detect...
Bionano Laboratories Announces New Category I CPT Code for OGM Use in Hematological Malignancy Analysis
17. Juni 2024 16:05 ET
|
Bionano Laboratories
American Medical Association issues Category I CPT code for the use of optical genome mapping in genome-wide analysis related to hematological malignancies
Bionano Announces Series of Major Advancements to its Suite of Computational Tools for Comprehensive Cancer Analysis
09. Mai 2024 08:00 ET
|
Bionano Genomics
Bionano announces significant advancements to its suite of computational tools for comprehensive cancer analysis.
Correction: ImCheck to Present New Positive Data on ICT01 Monotherapy in Hematological Cancers at ESMO 2023
18. Oktober 2023 15:50 ET
|
ImCheck Therapeutics SAS
ImCheck to Present New Positive Data on ICT01 Monotherapyin Hematological Cancers at ESMO 2023 Interim data from Phase I dose escalation portion of EVICTION Phase I/IIa trialshow strong safety...
ImCheck to Present New Positive Data on ICT01 Monotherapy in Hematological Cancers at ESMO 2023
15. Oktober 2023 18:05 ET
|
ImCheck Therapeutics SAS
ImCheck to Present New Positive Data on ICT01 Monotherapyin Hematological Cancers at ESMO 2023 Interim data from Phase I dose escalation portion of EVICTION Phase I/IIa trialshow strong safety...
Rhizen Pharmaceuticals S.A. and Curon Biopharmaceutical Limited Announce an Exclusive Licensing Agreement to Develop and Commercialize Tenalisib, a Dual PI3K Delta and Gamma Inhibitor for Oncology in Greater China
12. Oktober 2020 08:00 ET
|
Rhizen Pharmaceuticals SA
La Chaux-de-Fonds, Switzerland and Shanghai, China. October 12, 2020, Oct. 12, 2020 (GLOBE NEWSWIRE) -- Rhizen Pharmaceuticals S. A. (Rhizen), a Switzerland-based privately held clinical-stage...
Hematological Malignancies Market to attain a valuation of US$51.9 billion by 2024 - TMR
19. März 2019 08:45 ET
|
Transparency Market Research
Albany, New York, March 19, 2019 (GLOBE NEWSWIRE) -- The TMR report projects the global hematological malignancies market to register an impressive CAGR of 7.50% from 2016 to 2024. The market was...
Abstract från AroCell accepterad för posterpresentation under AACR 2019
28. Februar 2019 04:30 ET
|
AroCell AB
Ett abstract från AroCell har accepterats för posterpresentation på American Association of cancer Research 2019 (AACR 2019) som hålls mellan 29 mars och 3 april i Atlanta, Georgia, USA. Studien...
Abstract from AroCell accepted for poster presentation during AACR 2019
28. Februar 2019 04:30 ET
|
AroCell AB
An abstract from AroCell has been accepted for poster presentation on the American Association of Cancer Research 2019 (AACR 2019) held from March 29 to April 3 in Atlanta, Georgia, USA. The Study...